Key Financial Highlights (Standalone)
(₹ in lakh)| Particulars | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | 9M FY2025 | 9M FY2024 | FY2024 (Audited) |
|---|---|---|---|---|---|---|
| Revenue from Operations | 3,292.11 | 4,115.51 | 3,141.52 | 10,418.09 | 7,941.22 | 10,693.63 |
| Total Income | 3,379.54 | 4,128.45 | 3,194.01 | 10,580.41 | 8,066.99 | 10,804.35 |
| Total Expenses | 3,020.60 | 3,801.53 | 2,953.85 | 9,660.08 | 8,044.38 | 10,892.07 |
| Profit Before Tax | 358.94 | 326.82 | 240.16 | 920.10 | 22.61 | (87.73) |
| Net Profit After Tax | 269.85 | 247.29 | 136.46 | 692.10 | (69.47) | (226.79) |
| Earnings Per Share (₹) | 0.75 | 0.69 | 0.40 | 1.93 | (0.22) | (0.72) |
- Quarterly Revenue Decline: The company recorded a 20% sequential decline in revenue from operations in Q3 FY2025 (₹3,292.11 lakh) compared to Q2 FY2025 (₹4,115.51 lakh).
- Year-on-Year Growth: Revenue grew by 4.8% YoY, rising from ₹3,141.52 lakh in Q3 FY2024.
- Profitability Improvement: Net profit after tax for Q3 FY2025 stood at ₹269.85 lakh, compared to ₹136.46 lakh in Q3 FY2024, reflecting a 97.7% YoY increase.
- EPS Improvement: Basic and diluted earnings per share increased to ₹0.75, from ₹0.40 in Q3 FY2024.
Key Financial Highlights (Consolidated)
(₹ in lakh)| Particulars | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | 9M FY2025 | 9M FY2024 | FY2024 (Audited) |
|---|---|---|---|---|---|---|
| Revenue from Operations | 3,379.76 | 4,115.51 | 3,256.38 | 10,506.67 | 8,342.73 | 11,149.46 |
| Total Income | 3,462.38 | 4,118.17 | 3,310.58 | 10,648.28 | 8,458.38 | 11,263.49 |
| Total Expenses | 3,105.50 | 3,850.93 | 2,981.99 | 9,810.00 | 8,460.00 | 11,250.55 |
| Profit Before Tax | 357.21 | 267.25 | 328.65 | 838.19 | (113.00) | (87.06) |
| Net Profit After Tax | 270.83 | 209.65 | 178.10 | 624.00 | (55.22) | (248.92) |
| Earnings Per Share (₹) | 0.75 | 0.58 | 0.53 | 1.74 | (0.19) | (0.79) |
- Consolidated Revenue: Q3 FY2025 revenue stood at ₹3,379.76 lakh, reflecting a 3.8% YoY increase and a 17.8% QoQ decline.
- Profitability Growth: Net profit for Q3 FY2025 grew 52% YoY, reaching ₹270.83 lakh.
- EPS Strengthening: Earnings per share rose to ₹0.75 in Q3 FY2025, up from ₹0.53 in Q3 FY2024.
Segment-Wise Performance
- Pharmaceuticals: The company operates solely in the pharmaceutical segment, continuing to strengthen its market position.
Auditor's Review and Observations
- The statutory auditors, D. Kothary & Co., issued an unqualified opinion on both standalone and consolidated financial statements.
- No material misstatements or regulatory non-compliances were identified.
Management Commentary
Kunal Gandhi, Managing Director & CEO, stated:"We continue to see strong year-on-year growth in revenue and profitability, driven by our strategic focus on operational efficiency and market expansion. While Q3 revenue declined sequentially, we remain optimistic about sustained growth in the coming quarters."
Strategic Outlook
- The company expects steady revenue growth driven by expansion in domestic and export markets.
- Operational efficiencies and cost management initiatives are expected to further improve profitability.
- No outstanding defaults on loans or debt securities were reported.
Lyka Labs remains committed to delivering shareholder value through continued expansion and strong financial performance.